IRAK4 deficiency

IRAK4 Deficiency (Immunodeficiency 67)

Overview

IRAK4 deficiency is a rare, autosomal recessive primary immunodeficiency of innate immunity caused by biallelic loss‑of‑function variants in the IRAK4 gene encoding interleukin‑1 receptor‑associated kinase 4. Major rare‑disease databases classify this condition under the name “immunodeficiency 67” and list multiple synonymous labels, including:[1][2][3][4][5][6]

• IRAK4 deficiency / IRAK‑4 deficiency
• Immunodeficiency due to interleukin‑1 receptor‑associated kinase‑4 deficiency
• Interleukin receptor‑associated kinase deficiency
• Invasive pneumococcal disease, recurrent isolated type 1 (IPD1)

The hallmark of IRAK4 deficiency is marked susceptibility to invasive, life‑threatening infections with pyogenic (pus‑forming) bacteria, especially Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa, in early childhood. Infections tend to become less frequent and less severe after adolescence, although serious infections can still occur.[7][8][1]

Role of IRAK4 in innate immunity

TLR/IL‑1 receptor signaling pathway

IRAK4 is a serine/threonine kinase that plays a central role in signaling downstream of most Toll‑like receptors (TLRs) and the interleukin‑1 receptor (IL‑1R). Upon recognition of microbial components, TLRs recruit the adaptor protein MyD88, which in turn recruits and activates IRAK4; activated IRAK4 then phosphorylates IRAK1 and other downstream molecules, culminating in activation of NF‑κB and MAP kinase pathways and production of pro‑inflammatory cytokines such as tumor necrosis factor (TNF), interleukin‑6 (IL‑6), and interleukin‑1β (IL‑1β).[9][4][10][6][7]

In patients with IRAK4 deficiency, MyD88‑dependent TLR signaling is severely impaired. Functional studies show markedly reduced cytokine production by peripheral blood mononuclear cells in response to ligands of TLR2, TLR4, TLR5, TLR7, TLR8, and TLR9, and reduced shedding of CD62L from granulocytes after stimulation. In contrast, MyD88‑independent pathways such as TLR3 and parts of the TLR4‑interferon axis, as well as RIG‑I/MDA5 antiviral pathways, remain largely intact, explaining why viral susceptibility is not markedly increased.[6][7][9]

Genetic basis

The IRAK4 gene is located on chromosome 12q12 and encodes the interleukin‑1 receptor‑associated kinase 4 protein. MedlinePlus Genetics and ClinVar describe multiple pathogenic and likely pathogenic IRAK4 variants (nonsense, frameshift, splice‑site, and missense) that abolish protein expression or disrupt interaction with MyD88, leading to loss of function. Reactome’s curated pathway entry highlights variants such as
Q293[11][12][9][1]del* and E402* (truncating) and R12C (missense) as functionally characterized disease‑causing alleles.[9]

Epidemiology

IRAK4 deficiency is very rare, and precise prevalence is unknown. MedlinePlus Genetics notes that at least 49 individuals had been reported in the literature as of its last review. Subsequent case series and individual reports from Europe, North America, Asia, and the Middle East indicate additional patients but still only a few dozen families worldwide.[8][4][1][6]

Both males and females are affected equally, reflecting the autosomal recessive inheritance pattern. Many reported patients are from consanguineous families or populations with higher rates of consanguinity, consistent with recessive inheritance.[2][4][1][6]

Pathophysiology

Because IRAK4 sits at a critical convergence point for MyD88‑dependent TLR and IL‑1R signaling, its absence leads to a selective defect in the innate immune response to pyogenic bacteria. Key pathophysiologic features include:[10][7][6]

• Defective recognition and response to Gram‑positive encapsulated bacteria such as S. pneumoniae and S. aureus.[7][1]
• Failure to appropriately produce early pro‑inflammatory cytokines (IL‑6, TNF, IL‑1β) and chemokines in response to TLR ligands, resulting in a blunted inflammatory response.[4][7][9]
• Relative preservation of antiviral and antifungal pathways, which rely more on MyD88‑independent TLRs and cytosolic nucleic acid sensors.[6][9]

A clinically important consequence is that patients may experience severe, invasive bacterial infections without the usual signs of systemic inflammation, particularly absent or low‑grade fever and low inflammatory markers (ESR/CRP) despite sepsis. Adaptive immune parameters (immunoglobulin levels, specific antibody responses, and T‑ and B‑cell subsets) are usually normal, highlighting that this is a primarily innate immune defect.[1][4][7]

Clinical manifestations

Age of onset and natural history

Most affected individuals present in infancy or early childhood. MedlinePlus Genetics notes that the majority experience their first serious bacterial infection before age 2. A comprehensive clinical summary from Immunodeficiency Search and published case reports indicate that mortality may reach 30–40% in the first decade of life, with most deaths occurring before age 8.[8][4][7][1]

Strikingly, the incidence and severity of infections decline with age, and very few severe infections or deaths are reported after adolescence, suggesting partial compensation by maturation of adaptive immunity and other host defenses.[7][1][6]

Types of infections

Trusted sources (MedlinePlus Genetics, NORD/Global Genes, Immunodeficiency Search, and case reports) consistently describe a characteristic infection profile:[3][2][1][8][7]

• Invasive bacterial infections:
  • Septicemia (bacteremia).
  • Meningitis (often pneumococcal).
  • Osteomyelitis and septic arthritis.
  • Deep soft‑tissue and organ abscesses.
• Pathogens predominantly include:
  • Streptococcus pneumoniae.
  • Staphylococcus aureus.
  • Pseudomonas aeruginosa; other Gram‑negative bacilli have been reported in some patients.[1][8][7]
• Localized infections:
  • Recurrent otitis media, sinusitis, and pneumonia.
  • Skin and soft‑tissue infections, cellulitis, and abscesses.
  • Conjunctivitis and other superficial infections.

Unlike many other primary immunodeficiencies, there is no clear predisposition to opportunistic fungal infections, mycobacterial disease, or severe viral infections, although minor viral and fungal infections can occur at population‑level frequencies.[6][7][1]

Blunted inflammatory signs

A distinctive clinical feature emphasized by Immunodeficiency Search, MedlinePlus, and multiple case series is a poor febrile and acute‑phase response:[4][7][1]

• Many patients do not mount high fevers, even during severe sepsis or meningitis.
• Laboratory markers such as C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) may be only mildly elevated or even normal.

This blunted response can delay recognition of serious infection and is an important clinical clue to the diagnosis.

Other features

Beyond infections, most individuals with IRAK4 deficiency have normal growth, development, and physical examination between infectious episodes. Autoimmune disease and malignancy have not emerged as consistent features of this condition in available reports.[4][1][6]

Immunologic and laboratory findings

Common immunologic findings include:[7][4][6]

• Normal or near‑normal quantitative immunoglobulin levels (IgG, IgA, IgM).
• Normal specific antibody responses to protein and polysaccharide vaccines (though recurrent infections still occur).
• Normal T‑cell and B‑cell numbers and phenotypes.

Functional assays, however, reveal profound defects:

• TLR function tests using patient peripheral blood mononuclear cells show markedly reduced production of IL‑6, TNF, and IL‑1β in response to TLR1/2, TLR2/6, TLR4, TLR5, TLR7, TLR8, and TLR9 agonists.[9][6][7]
• CD62L shedding from granulocytes after TLR stimulation is absent or severely reduced.[9][4]

Routine laboratory tests during infections may show bacteremia on blood culture and local inflammatory changes, but fevers and acute‑phase reactants may be muted as described above.[1][7]

Diagnosis

When to suspect IRAK4 deficiency

Clinicians should suspect IRAK4 deficiency in children (and occasionally adults) with:[2][4][7][1]

• Recurrent or severe invasive pyogenic bacterial infections (sepsis, meningitis, osteomyelitis, deep abscesses), particularly with S. pneumoniae, S. aureus, or P. aeruginosa.
• Onset in early childhood, often before age 2.
• Poor febrile response and low inflammatory markers despite severe infection.
• Largely normal adaptive immune evaluation (immunoglobulins, lymphocyte subsets, specific antibodies).
• Family history consistent with autosomal recessive inheritance, especially in consanguineous families.

Diagnostic work‑up

Work‑up follows standard primary immunodeficiency evaluation as recommended by specialty organizations such as the Immune Deficiency Foundation and primary immune disorder guidelines:[10][4]

• Baseline tests: complete blood count with differential, immunoglobulins, specific antibody titers, lymphocyte subsets.
• Functional TLR assays, where available, to assess cytokine production in response to TLR ligands.
• Molecular genetic testing for IRAK4 variants via:
  • Targeted sequencing in patients with a strong clinical suspicion.
  • Primary immunodeficiency gene panels.
  • Whole‑exome or whole‑genome sequencing in undiagnosed cases.

MedlinePlus Genetics and NORD/Global Genes emphasize that the definitive diagnosis requires identification of biallelic pathogenic variants in IRAK4 compatible with autosomal recessive inheritance.[3][2][1]

Differential diagnosis

The main differential diagnoses involve other innate immune defects affecting TLR/IL‑1 pathways or increasing susceptibility to invasive bacterial infections:[13][10][4]

• MyD88 deficiency: clinically very similar, with recurrent invasive infections by S. pneumoniae, S. aureus, and P. aeruginosa; also autosomal recessive and affects the same pathway upstream of IRAK4.
• Other TLR signaling defects (e.g., TLR2, TLR4, TLR5, TLR3 deficiencies): may have narrower or different infection profiles (e.g., herpes simplex encephalitis in TLR3 deficiency).
• Complement deficiencies (e.g., C2, C3, properdin, terminal complement components): predispose to invasive bacterial infections, especially Neisseria species, and may show low complement levels or hemolytic activity.
• Antibody deficiencies (e.g., common variable immunodeficiency, specific antibody deficiency): recurrent sinopulmonary infections, but often broader pathogen range and abnormal antibody responses.

Careful clinical evaluation, complement and antibody testing, and targeted genetic analysis help distinguish these conditions.

Management

General principles

There is no curative, pathway‑targeted therapy for IRAK4 deficiency at present; management focuses on aggressive prevention and early treatment of bacterial infections, following general recommendations for severe pyogenic infection–prone primary immunodeficiencies from the Immune Deficiency Foundation and other expert groups.[10][7]

Infection prevention

Key preventive strategies include:[3][10][7]

• Antibiotic prophylaxis:
  • Long‑term prophylactic oral antibiotics (e.g., penicillin, amoxicillin, or alternatives based on local resistance patterns) to reduce the risk of pneumococcal and staphylococcal infections.
• Immunoglobulin replacement therapy:
  • Many centers administer monthly intravenous or subcutaneous immunoglobulin (IVIG/SCIG) as adjunctive prophylaxis, even though antibody production is often normal, to confer broad opsonizing antibodies against encapsulated bacteria.[7]
• Vaccinations:
  • Strict adherence to routine immunization schedules, with special emphasis on pneumococcal (conjugate and polysaccharide), Haemophilus influenzae type b, and meningococcal vaccines.[10]
  • Annual influenza vaccination to reduce secondary bacterial complications.

Immunodeficiency Search suggests continuing antibiotic prophylaxis and/or IVIG at least until the mid‑teen years (~16 years), when risk of life‑threatening infections appears to decline. Individualized decisions should be made by immunology specialists.[7]

Early recognition and aggressive treatment of infections

Because inflammatory signs may be blunted, families and clinicians must maintain a low threshold for evaluating possible infection and initiating treatment:[4][1][7]

• Educate caregivers to seek prompt medical attention for any signs of illness (e.g., decreased activity, poor feeding, irritability, localized pain), even without fever.
• Early empiric broad‑spectrum intravenous antibiotics for suspected serious infection, tailored based on local susceptibility patterns and prior culture results.
• Hospitalization and intensive monitoring for sepsis or meningitis.

Supportive care

General supportive measures include attention to nutrition, routine health maintenance, and psychosocial support for families coping with a chronic rare disorder.[2][3][10]

Prognosis

Prognosis in IRAK4 deficiency is bimodal:[8][1][4][7]

• High risk in early childhood: Mortality rates up to approximately 30–40% in the first decade, primarily from overwhelming sepsis or meningitis, have been reported in earlier cohorts before widespread use of prophylaxis and modern intensive care.
• Improved outlook after adolescence: Very few deaths or severe infections have been reported in patients older than 14–16 years, suggesting that maturation of adaptive immunity and other defenses partly compensates for the innate defect.

With early diagnosis, comprehensive prophylaxis, and rapid treatment of infections, many children now survive into adulthood, though precise long‑term outcome data remain limited due to the rarity of the condition. Quality of life between infections can be normal, provided that serious infections are prevented or promptly managed.[8][6][1][4]

Genetic counseling

IRAK4 deficiency is inherited in an autosomal recessive manner.[2][1]

• When both parents are carriers of a pathogenic IRAK4 variant, each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of an unaffected non‑carrier.
• Siblings of an affected individual should be offered genetic testing and immunologic evaluation; early identification allows timely initiation of prophylaxis.[3][2]

Once the disease‑causing variants are known, carrier testing for at‑risk relatives and options for prenatal diagnosis or preimplantation genetic testing can be discussed with families, ideally in the context of specialized genetic counseling.

Research directions

Ongoing research in IRAK4 deficiency and related innate immune disorders focuses on:[13][6][9]

• Better defining the natural history and age‑related changes in infection risk through international registries.
• Elucidating how specific IRAK4 mutations alter protein structure, MyD88 interaction, and downstream signaling, potentially identifying hypomorphic versus null alleles.
• Exploring targeted therapies that may modulate innate immune responses or compensate for TLR/IL‑1R signaling defects, although such treatments remain experimental.
• Understanding broader implications of IRAK4 and related kinases in chronic inflammatory diseases, which has informed drug development of small‑molecule IRAK4 inhibitors—primarily for autoimmune and inflammatory indications rather than for immunodeficiency.[14][15]

Rare‑disease infrastructures such as NORD, Orphanet (via Orphadata), GARD, and Global Genes provide up‑to‑date summaries, patient resources, and links to clinical trials and registries for immunodeficiency 67 (IRAK4 deficiency).[12][2][3]

---

References

1. IRAK-4 deficiency – Genetics – MedlinePlus – IRAK-4 deficiency is an inherited disorder of the immune system (primary immunodeficiency). Explore …
2. immunodeficiency 67 – Interleukin receptor-associated kinase deficiency; immunodeficiency 67; immunodeficiency due to inte…
3. Immunodeficiency due to interleukin-1 receptor-associated … – Synonyms: IRAK4 deficiency. Interleukin-1 receptor-associated kinase-4 (IRAK-4) deficiency is an imm…
4. IRAK4 Deficiency in a Patient with Recurrent … – Primary immunodeficiencies are genetic defects of the innate or adaptive immune system, resulting in…
5. IRAK4 deficiency | Disease page – Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency. Database Links. OMIM:…
6. Interleukin-1 Receptor-Associated Kinase 4 Deficiency in a Greek Teenager – Human interleukin- (IL-) 1 receptor-associated kinase 4 (IRAK-4) deficiency is a recently described …
7. IRAK4 Deficiency – Immunodeficiency Search – Irak4
8. Case of Fatal Meningitis in an Adult Patient with IRAK4 …
9. IRAK4 deficiency (TLR2/4) – IRAK4 deficiency (TLR2/4) ; 15069402, Primary immunodeficiency to pneumococcal infection due to a de…
10. Innate immune disorders – Since Myd88 recruits and interacts with another protein called interleukin-1 receptor-associated kin…
11. NM_016123.4(IRAK4):c.490+16A>C AND Immunodeficiency 67 – Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency; Identifiers: MONDO: M…
12. IRAK4-interleukin 1 receptor associated kinase 4 – Knowledge on rare diseases and orphan drugs · Search for a gene · IRAK4 – interleukin 1 receptor ass…
13. Oral Diseases as a Manifestation of Inborn Errors of Immunity – by K Napiórkowska-Baran · 2024 · Cited by 8 — Defects in specific TLR signaling components like inte…
14. Nonhematopoietic IRAK1 drives arthritis via neutrophil … – by T Hoyler · 2022 · Cited by 8 — The critical role of kinase activity of interleukin-1 receptor-ass…
15. Preliminary findings from single cell RNA sequencing and … – by M Bekhbat · 2022 · Cited by 18 — … interleukin-1 receptor-associated kinase 4; AMP kinase, AMP-…